SMi’s 6th annual Biomarkers Summit 2013 - Innovations is stratified medicine

Drawing on advances in genomics, translational medicine and clinical trial design, SMi’s sixth annual Biomarkers Summit held on 16th &17th January 2013 London brings you the latest developments from toxicity testing to compound screening and first-in-man studies to companion diagnostic assays, stay competitive with fresh insights from companies at the cutting edge of biopharmaceutical development.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

London (PRWEB UK) 18 September 2012

The drive towards personalized medicine is seeing pharma move from patient stratification as a ‘nice to have’, to an essential feature of product development. Exemplified by the success of Herceptin, biomarkers promise to transform drug discovery, clinical development and diagnostics in the R&D process. This dynamic market, poised to reach a value of $33.3 billion by 2015, will continue to improve decision-making, clinical trial success rates and translational productivity.

Attending will enable you to:

  •     Accelerate companion diagnostics development for therapeutic indications

  •     Validate and deliver biomarkers for patient selection during clinical trials

  •     Implement sub-grouping in patient segmentation studies

  •     Utilise revised FDA regulatory guidelines to aid product development

  •     Optimise reimbursement strategies for diagnostics

  •     Maximise biomarker identification using epigenetic and metabolomic insights
For more information visit http://www.smi-online.co.uk/goto/biomarkers-summit13.asp alternatively contact Farhaana Rahman on +44 0 207 827 6186 or email on frahman(at)smi-online.co(dot)uk

Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
PDF Version PDF Printer Friendly VersionPrint

Contact

  • Sonal Patel
    SMi Group Ltd
    0207 827 6106
    Email
Follow us on: Contact's Twitter